Document Detail

Optic neuritis associated with adalimumab in the treatment of uveitis.
MedLine Citation:
PMID:  20809867     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Tumor necrosis factor (TNF) inhibitors such as adalimumab are increasingly used in the treatment of ocular inflammatory disease refractory to standard therapies. There is evidence that TNF inhibitors are associated with demyelinating neurologic events.
OBJECTIVE: The authors report a case of optic neuritis and multiple sclerosis developing in association with the use of adalimumab for the treatment of bilateral chronic granulomatous iridocyclitis and multifocal choroiditis. They also review the available literature on cases of optic neuritis occurring in the setting of TNF inhibition.
RESULTS: The authors identified 21 cases of optic neuritis associated with TNF inhibition; 36% of cases with available MRI results had evidence of other demyelinating lesions in the CNS.
CONCLUSIONS: The strong association between TNF inhibitors and CNS demyelination may represent an adverse effect of these drugs. Ophthalmologists should recognize the relationship between TNF inhibitors and demyelinating disease, as it can present initially with visual symptoms.
Sing Your Li; Andrea D Birnbaum; Debra A Goldstein
Related Documents :
12452747 - Quetiapine therapy for posttraumatic stress disorder.
23530967 - Primary hodgkin lymphoma of the central nervous system: two case reports and review of ...
23863347 - Calcifying pseudoneoplasm of the neuraxis overlying the corpus callosum: a case report ...
19874337 - Therapeutic options for palmoplantar pustulosis.
1374757 - Cd7-positive acute myeloid leukemia: further evidence of cellular immaturity.
15779487 - Primary appendiceal lymphoma presenting as perforated acute appendicitis.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-09-01
Journal Detail:
Title:  Ocular immunology and inflammation     Volume:  18     ISSN:  1744-5078     ISO Abbreviation:  Ocul. Immunol. Inflamm.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-03-18     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9312169     Medline TA:  Ocul Immunol Inflamm     Country:  England    
Other Details:
Languages:  eng     Pagination:  475-81     Citation Subset:  IM    
Department of Ophthalmology and Visual Sciences, University of Illinois, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use
Anti-Inflammatory Agents / adverse effects*,  therapeutic use
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Antibodies, Monoclonal, Humanized
Brain / pathology
Drug Administration Schedule
Injections, Intravenous
Interferon-beta / therapeutic use
Iridocyclitis / chemically induced*,  diagnosis,  drug therapy,  physiopathology
Magnetic Resonance Imaging
Methylprednisolone / administration & dosage
Multiple Sclerosis / chemically induced*,  diagnosis,  drug therapy,  physiopathology
Optic Neuritis / chemically induced*,  diagnosis,  drug therapy,  physiopathology
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Uveitis / drug therapy*
Visual Fields
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta; 83-43-2/Methylprednisolone; FYS6T7F842/adalimumab
Comment In:
Ocul Immunol Inflamm. 2010 Dec;18(6):421-3   [PMID:  21091055 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  One-year effects of vitamin D and calcium supplementation on chronic periodontitis.
Next Document:  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.